Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/BIO stock hub

FRA/BIO has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/BIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.4B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/BIOFRA/BIO

—

Loading chart…

In the news

Latest news · FRA/BIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-4.7

P25 n/aP50 n/aP75 n/a

ROIC1.1

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/BIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

186

Groups with data

Currency

EUR

Showing 186 of 186 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Germany
Country code	DE
Employees	2,495
Employees Change	69%
Employees Change Percent	2.84
Enterprise value	EUR 2B
Exchange	Frankfurt Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.4B
Price	EUR 42.2
Price currency	EUR
Rev Per Employee	254,589.18x
Sic	2836
Symbol	fra/BIO
Website	https://www.biotest.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.73%
EV Earnings	-83.41x
EV/EBIT	268.89x
EV/EBITDA	41.73x
EV/FCF	-142.91x
EV/Sales	3.22x
FCF yield	-1.01%
P/B ratio	2.78x
P/S ratio	2.23x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	1.89%
EBITDA Margin	7.36%
Gross margin	23.19%
Gross Profit	EUR 147.3M
Gross Profit Growth	-57.45%
Gross Profit Growth Q	-84.44%
Gross Profit Growth3 Y	20.64%
Gross Profit Growth5 Y	1.34%
Net Income	EUR -24.5M
Pretax Margin	-4.03%
Profit Margin	-3.86%
Profit Per Employee	EUR -9,820
ROA	0.52
Roa5y	1.01
ROCE	0.96
ROE	-4.72
Roe5y	0.72
ROIC	1.08
Roic5y	1.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	4.95%
Cagr15y	8.93%
Cagr1y	2.93%
Cagr20y	10.6%
Cagr3y	0.08%
Cagr5y	13.92%
Div CAGR10	7.18%
OCF Growth	-37.39%
OCF Growth10 Y	-0.14%
OCF Growth3 Y	-40.74%
Revenue Growth	-18.84x
Revenue Growth Q	-42.29x
Revenue Growth3 Y	7.49x
Revenue Growth5 Y	7.65x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.44
Assets	EUR 1.4B
Cash	EUR 41.8M
Current Assets	EUR 788.7M
Current Liabilities	EUR 160.1M
Debt	EUR 668.7M
Debt EBITDA	EUR 12.53
Debt Equity	EUR 1.31
Debt FCF	EUR -46.76
Equity	EUR 509.6M
Interest Coverage	0.4
Liabilities	EUR 906.9M
Long Term Assets	EUR 627.8M
Long Term Liabilities	EUR 746.8M
Net Cash	EUR -626.9M
Net Cash By Market Cap	EUR -44.25
Net Debt EBITDA	EUR 13.4
Net Debt Equity	EUR 1.23
Tangible Book Value	EUR 493.3M
Tangible Book Value Per Share	EUR 12.68

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.93
Inventory Turnover	1.01
Net Working Capital	EUR 615.7M
Quick ratio	1.49
Working Capital	EUR 628.6M
Working Capital Turnover	EUR 1.23

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	1.46%
Dividend per share	EUR 0
Last Dividend	EUR 0.04

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	62.19%
1Y total return	2.93%
200-day SMA	41.21
3Y total return	0.24%
50-day SMA	42.03
50-day SMA vs 200-day SMA	50over200
5Y total return	91.82%
All Time High	44.8
All Time High Change	-5.8%
All Time High Date	2023-10-05
All Time Low	1.03
All Time Low Change	3,985.19%
All Time Low Date	2003-04-01
ATR	0.19
Ch YTD	2.93
High	42.2
High52	42.8
High52 Date	2025-06-02
High52ch	-1.4%
Low	42.2
Low52	40
Low52 Date	2025-03-27
Low52ch	5.5%
Ma50ch	0.41%
Price vs 200-day SMA	2.4%
RSI	50.21
RSI Monthly	57.89
RSI Weekly	59.43
Sharpe ratio	0x
Sortino ratio	0.55
Total Return	1.46%
Tr YTD	2.93
Tr15y	260.96%
Tr1m	0.48%
Tr1w	-0.47%
Tr3m	4.46%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 12M
Operating Income Growth	-93.28
Operating margin	1.89

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	20,351,598%
Net Borrowing	-32,800,000
Shares Institutions	0.44%
Shares Qo Q	0.58%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -14.3M
Average Volume	1.5x
Bv Per Share	13.1
CAPEX	EUR -28.7M
Ch10y	61.41
Ch15y	244.4
Ch1m	0.48
Ch1w	-0.47
Ch1y	2.93
Ch20y	569.8
Ch3m	4.46
Ch3y	0.24
Ch5y	91.82
Ch6m	2.93
Change	0%
Change From Open	0
Close	42.2
Days Gap	0
Depreciation Amortization	34,775,000
Earnings Date	2026-05-13
EBIT	EUR 12M
EBITDA	EUR 46.8M
EPS	EUR -0.63
F Score	4
FCF	EUR -14.3M
FCF EV Yield	-0.7x
Financing CF	-40,400,000
Fiscal Year End	December
Founded	1,946
Income Tax	EUR -1.1M
Investing CF	-16,900,000
Is Primary Listing	0
Last Earnings Date	2025-11-10
Last Report Date	2025-03-31
Last Split Date	2015-07-15
Last Split Type	Forward
Ma150	41.22
Ma150ch	2.39%
Ma20	42.31
Ma20ch	-0.26%
Net CF	-43,000,000
Next Earnings Date	2026-05-13
Open	42.2
P OCF Ratio	98.38
Ppne	566,800,000
Price Date	2025-06-06
Price EBITDA	EUR 30.29
Ptbv Ratio	2.87
Relative Volume	48.22x
Revenue	635,200,000x
Tax By Revenue	-0.17x
Tr20y	650.27%
Tr6m	2.93%
Z Score	1.97

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/BIO pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/BIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/BIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+0.4%

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

FRA/BIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

50.2

Neutral momentum band

Price vs 200-day MA

+2.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.00

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/BIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/BIO stock rating?

fra/BIO is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/BIO analysis?

The full report lives at /stocks/fra/BIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/BIO?

The latest report frames fra/BIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/BIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.